M. Qiu, Yang Zhang, Ye Guo, W. Guo, Weiqi Nian, W. Liao, Zhongyuan Xu, Wenxue Zhang, Hongzhe Zhao, Xiaoli Wei, L. Xue, W. Tang, Yunteng Wu, G. Ren, Ling Wang, Jingle Xi, Yongshuai Jin, Hu Li, Chaohong Hu, R. Xu
{"title":"Evaluation of Safety of Treatment With Anti–Epidermal Growth Factor Receptor Antibody Drug Conjugate MRG003 in Patients With Advanced Solid Tumors","authors":"M. Qiu, Yang Zhang, Ye Guo, W. Guo, Weiqi Nian, W. Liao, Zhongyuan Xu, Wenxue Zhang, Hongzhe Zhao, Xiaoli Wei, L. Xue, W. Tang, Yunteng Wu, G. Ren, Ling Wang, Jingle Xi, Yongshuai Jin, Hu Li, Chaohong Hu, R. Xu","doi":"10.1001/jamaoncol.2022.0503","DOIUrl":null,"url":null,"abstract":"Key Points Question What is the safety and antitumor activity of MRG003 in patients with advanced solid tumors? Findings In this phase 1 clinical trial of 61 patients with advanced or metastatic solid tumors, treatment with MRG003 exhibited manageable safety and showed encouraging antitumor activity in squamous cell carcinomas of the head and neck and nasopharyngeal carcinoma, with a confirmed objective response rates of 40% and 44%, respectively. Meaning The study findings suggest the safety of treatment with MRG003 and an acceptable tolerance in most patients with epidermal growth factor receptor–expressing solid tumors, as well as encouraging antitumor activity in patients with squamous cell carcinomas of the head and neck and nasopharyngeal carcinoma.","PeriodicalId":14850,"journal":{"name":"JAMA Oncology","volume":"8 1","pages":"1042 - 1046"},"PeriodicalIF":22.5000,"publicationDate":"2022-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"9","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAMA Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1001/jamaoncol.2022.0503","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 9
Abstract
Key Points Question What is the safety and antitumor activity of MRG003 in patients with advanced solid tumors? Findings In this phase 1 clinical trial of 61 patients with advanced or metastatic solid tumors, treatment with MRG003 exhibited manageable safety and showed encouraging antitumor activity in squamous cell carcinomas of the head and neck and nasopharyngeal carcinoma, with a confirmed objective response rates of 40% and 44%, respectively. Meaning The study findings suggest the safety of treatment with MRG003 and an acceptable tolerance in most patients with epidermal growth factor receptor–expressing solid tumors, as well as encouraging antitumor activity in patients with squamous cell carcinomas of the head and neck and nasopharyngeal carcinoma.
期刊介绍：
JAMA Oncology is an international peer-reviewed journal that serves as the leading publication for scientists, clinicians, and trainees working in the field of oncology. It is part of the JAMA Network, a collection of peer-reviewed medical and specialty publications.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
